No Application Received from SII: EMA on Covishield EU Approval

In a press briefing on 16 July, EMA stated that it has not received any formal marketing authorisation application.

1 min read
<div class="paragraphs"><p>The European Medicines Agency (EMA) has not received any request for approval of authorisation of Covishield.</p></div>

The European Medicines Agency (EMA) on Friday, 16 July stated that it has not received any application for authorisation from Serum Institute of India (SII) for its COVID-19 vaccine Covishield.

In a press briefing, the EMA stated that 'the developer needs to submit a formal marketing authorisation application to EMA, which to date has not been received'.

The European Medicines Agency (EMA) has so far cleared four vaccines – Comirnaty (Pfizer/BioNTech), Moderna, Vaxzervria (AstraZeneca manufactured in the UK and EU countries), and Janssen (Johnson & Johnson).


Quoting SII CEO Adar Poonawalla, The Times of India reported that the vaccine manufacturer is confident in receiving approval in a month from EMA.

"It is not a controversy, it is just blown out of proportion and the issue of vaccine passports should be on the basis of reciprocity between the countries,” said Poonawalla at Indian Global Forum, reported TOI.

Covishield has been excluded from Europes’s Green Pass scheme, reported The Wire Science on 28 June. The scheme, which came into effect on 1 July, serves as proof that the individual has been vaccinated against COVID-19, or has recently tested negative against it, or has natural immunity build up from an earlier version.

(At The Quint, we are answerable only to our audience. Play an active role in shaping our journalism by becoming a member. Because the truth is worth it.)

Stay Updated

Subscribe To Our Daily Newsletter And Get News Delivered Straight To Your Inbox.

Join over 120,000 subscribers!